News
Tabrecta Approved for METex14 Metastatic Non-Small Cell Lung Cancer
The Food and Drug Administration has granted accelerated approval to Tabrecta™ (capmatinib; Novartis).
Your search for non small cell lung cancer returned 277 results
News
Imfinzi Approved to Treat Stage III Non-Small Cell Lung Cancer
The approval of Imfinzi is based on the positive PFS data from the Phase 3 PACIFIC trial.
News
Tecentriq Approved for Non-Small Cell Lung Cancer
Genentech announced that the Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities.
Drugs in the Pipeline
FDA Grants Xalkori Priority Review for Non-Small Cell Lung Cancer
The FDA has accepted and granted Priority Review for a supplemental New Drug Application (sNDA) for Xalkori (crizotinib; Pfizer).
News
FDA Approves Tagrisso to Treat Non-Small Cell Lung Cancer
The US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib; AstraZeneca) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.
News
Gilotrif, Companion Diagnostic Approved for Non-Small Cell Lung Cancer
The FDA has approved Gilotrif (afatinib) with the therascreen EGFR RQG PCR kit for the treatment of metastatic non-small cell lung carcinoma in patients whose tumors have certain EGFR gene mutations detected by the FDA-approved diagnostic test.
Drugs in the Pipeline
Phase 3 Trial Update of Sorafenib for Advanced Non Small-cell Lung Cancer
Sorafenib does not improve OS for patients with advanced NSCLC, but it may benefit a subset of patients whose tumors harbor EGFR mutations.
Drugs in the Pipeline
Phase 2b Trial Update of Bavituximab for Second-Line Non-Small Cell Lung Cancer
Peregrine Pharmaceuticals announced interim results from its randomized, double-blind, placebo-controlled Phase 2b trial of bavituximab in patients with refractory non-small cell lung cancer (NSCLC).
Drugs in the Pipeline
Phase 3 Trial Update of Alimta for Nonsquamous Non-Small Cell Lung Cancer
Eli Lilly and Company announced today that the Phase 3 POINTBREAK trial did not meet its primary endpoint of improved overall survival for patients with nonsquamous non-small cell lung cancer (NSCLC) who were randomized to receive a combination of Alimta (pemetrexed for injection) with bevacizumab (Avastin; Genentech) and carboplatin induction followed by Alimta plus bevacizumab maintenance-the Alimta arm-compared to the combination of paclitaxel (Taxol; Bristol-Myers Squibb) with bevacizumab and carboplatin followed by bevacizumab maintenance-the paclitaxel arm.
Drugs in the Pipeline
Phase 3 Trial Update of Afatinib for Advanced non-Small Cell Lung Cancer
Boehringer Ingelheim announced results from its LUX-Lung 3 Phase 3 clinical trial of afatinib in patients with advanced non-small cell lung cancer (NSCLC).
